Tyra Biosciences (TYRA) Competitors

Vericel (NASDAQ:VCEL) and Tyra Biosciences (NASDAQ:TYRA) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their community ranking, institutional ownership, dividends, earnings, risk, analyst recommendations, valuation, profitability and media sentiment.

Does the media prefer VCEL or TYRA?

In the previous week, Vericel had 19 more articles in the media than Tyra Biosciences. MarketBeat recorded 26 mentions for Vericel and 7 mentions for Tyra Biosciences. Vericel's average media sentiment score of 0.77 beat Tyra Biosciences' score of 0.36 indicating that Vericel is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vericel	9 Very Positive mention(s)	5 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tyra Biosciences	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral

Do analysts rate VCEL or TYRA?

Vericel presently has a consensus target price of $62.29, indicating a potential upside of 25.80%. Tyra Biosciences has a consensus target price of $30.50, indicating a potential upside of 172.08%. Given Tyra Biosciences' higher possible upside, analysts plainly believe Tyra Biosciences is more favorable than Vericel.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vericel	0 Sell rating(s)	0 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	3.00
Tyra Biosciences	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	3.00

Is VCEL or TYRA more profitable?

Vericel has a net margin of 1.56% compared to Tyra Biosciences' net margin of 0.00%. Vericel's return on equity of 1.48% beat Tyra Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vericel	1.56%	1.48%	0.96%
Tyra Biosciences	N/A	-24.56%	-23.31%

Do insiders & institutionals have more ownership in VCEL or TYRA?

84.1% of Tyra Biosciences shares are owned by institutional investors. 5.2% of Vericel shares are owned by insiders. Comparatively, 15.4% of Tyra Biosciences shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Which has more risk and volatility, VCEL or TYRA?

Vericel has a beta of 1.72, indicating that its stock price is 72% more volatile than the S&P 500. Comparatively, Tyra Biosciences has a beta of 1.05, indicating that its stock price is 5% more volatile than the S&P 500.

Which has better earnings & valuation, VCEL or TYRA?

Vericel has higher revenue and earnings than Tyra Biosciences. Tyra Biosciences is trading at a lower price-to-earnings ratio than Vericel, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vericel	$237.22M	10.30	-$3.18M	$0.18	275.06
Tyra Biosciences	N/A	N/A	-$69.13M	-$1.61	-6.96

Does the MarketBeat Community prefer VCEL or TYRA?

Vericel received 320 more outperform votes than Tyra Biosciences when rated by MarketBeat users. However, 75.56% of users gave Tyra Biosciences an outperform vote while only 61.89% of users gave Vericel an outperform vote.

Company	Underperform	Outperform
Vericel	Outperform Votes 354 61.89%	Underperform Votes 218 38.11%
Tyra Biosciences	Outperform Votes 34 75.56%	Underperform Votes 11 24.44%

Summary

Vericel beats Tyra Biosciences on 12 of the 16 factors compared between the two stocks.